Chronic Otitis Media (COM) - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Chronic Otitis Media (COM) - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Chronic Otitis Media (COM) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Chronic Otitis Media (COM): Overview
Chronic otitis media (COM) refers to a chronic infection of the middle ear cavity. It is caused due to an ongoing inflammatory response within the middle ear (with granulation), and is usually associated with unresolved and resistant bacterial infections. The infection can commonly occur in cold weather conditions, or if water enters the middle year. Any other ear infection can also cause this infection. Diagnosis involves physical examination of the patient’s ear, nose, and throat. If cholesteatoma is suspected, then it should be further investigated. The treatment options available are aural toileting and topical antibiotic (ciprofloxacin) and steroid drops (dexamethasone).
“Chronic Otitis Media (COM)- Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Otitis Media (COM) pipeline landscape is provided which includes the disease overview and Chronic Otitis Media (COM) treatment guidelines. The assessment part of the report embraces, in depth Chronic Otitis Media (COM) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Otitis Media (COM) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Otitis Media (COM) R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Otitis Media (COM).
Chronic Otitis Media (COM) Emerging Drugs Chapters
This segment of the Chronic Otitis Media (COM) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Otitis Media (COM) Emerging Drugs
Pazufloxacin mesilate: Lee's Pharmaceutical
Pazufloxacin is a fused tricyclic quinolone derivative that has a broad spectrum of anti-bacterial activity. Pazufloxacin inhibits bot DNA gyrase and topoisomerase IV and has shown in vitro activity against various bacterial species. The drug is in phase 1 of clinical trials for the treatment of chronic suppurative otitis media.
Further product details are provided in the report……..
Chronic Otitis Media (COM): Therapeutic Assessment
This segment of the report provides insights about the different Chronic Otitis Media (COM) drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Chronic Otitis Media (COM)
There are approx. 3+ key companies which are developing the therapies for Chronic Otitis Media (COM). The companies which have their Chronic Otitis Media (COM) drug candidates in the mid to advanced stage, i.e. phase III and Phase I include, Lee's Pharmaceutical and others.
Phases
DelveInsight’s report covers around 3+ products under different phases of clinical development like
Chronic Otitis Media (COM) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Chronic Otitis Media (COM): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Otitis Media (COM) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Otitis Media (COM) drugs.
Chronic Otitis Media (COM) Report Insights
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Chronic Otitis Media (COM) drugs? How many Chronic Otitis Media (COM) drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Otitis Media (COM)? What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Otitis Media (COM) therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Chronic Otitis Media (COM) and their status? What are the key designations that have been granted to the emerging drugs? Key Players
DelveInsight’s, “Chronic Otitis Media (COM) - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Chronic Otitis Media (COM) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Chronic Otitis Media (COM): Overview
Chronic otitis media (COM) refers to a chronic infection of the middle ear cavity. It is caused due to an ongoing inflammatory response within the middle ear (with granulation), and is usually associated with unresolved and resistant bacterial infections. The infection can commonly occur in cold weather conditions, or if water enters the middle year. Any other ear infection can also cause this infection. Diagnosis involves physical examination of the patient’s ear, nose, and throat. If cholesteatoma is suspected, then it should be further investigated. The treatment options available are aural toileting and topical antibiotic (ciprofloxacin) and steroid drops (dexamethasone).
“Chronic Otitis Media (COM)- Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Otitis Media (COM) pipeline landscape is provided which includes the disease overview and Chronic Otitis Media (COM) treatment guidelines. The assessment part of the report embraces, in depth Chronic Otitis Media (COM) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Otitis Media (COM) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Otitis Media (COM) R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Otitis Media (COM).
Chronic Otitis Media (COM) Emerging Drugs Chapters
This segment of the Chronic Otitis Media (COM) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Otitis Media (COM) Emerging Drugs
Pazufloxacin mesilate: Lee's Pharmaceutical
Pazufloxacin is a fused tricyclic quinolone derivative that has a broad spectrum of anti-bacterial activity. Pazufloxacin inhibits bot DNA gyrase and topoisomerase IV and has shown in vitro activity against various bacterial species. The drug is in phase 1 of clinical trials for the treatment of chronic suppurative otitis media.
Further product details are provided in the report……..
Chronic Otitis Media (COM): Therapeutic Assessment
This segment of the report provides insights about the different Chronic Otitis Media (COM) drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Chronic Otitis Media (COM)
There are approx. 3+ key companies which are developing the therapies for Chronic Otitis Media (COM). The companies which have their Chronic Otitis Media (COM) drug candidates in the mid to advanced stage, i.e. phase III and Phase I include, Lee's Pharmaceutical and others.
Phases
DelveInsight’s report covers around 3+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Chronic Otitis Media (COM) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Oral
- Parenteral
- Intramuscular
- Molecule Type
- Small molecules
- Peptides
- Polymer
- Gene therapy
- Monoclonal antibodies
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Chronic Otitis Media (COM): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Otitis Media (COM) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Otitis Media (COM) drugs.
Chronic Otitis Media (COM) Report Insights
- Chronic Otitis Media (COM) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- Lee's Pharmaceutical
- Pazufloxacin mesilate
Introduction
Executive Summary
Chronic Otitis Media (COM): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chronic Otitis Media (COM) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Chronic Otitis Media (COM) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Chronic Otitis Media (COM) Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Drug Name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Pazufloxacin mesilate: Lee's Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chronic Otitis Media (COM) Key Companies
Chronic Otitis Media (COM) Key Products
Chronic Otitis Media (COM)- Unmet Needs
Chronic Otitis Media (COM)- Market Drivers and Barriers
Chronic Otitis Media (COM)- Future Perspectives and Conclusion
Chronic Otitis Media (COM) Analyst Views
Chronic Otitis Media (COM) Key Companies
Appendix
Executive Summary
Chronic Otitis Media (COM): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chronic Otitis Media (COM) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Chronic Otitis Media (COM) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Chronic Otitis Media (COM) Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Drug Name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Pazufloxacin mesilate: Lee's Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chronic Otitis Media (COM) Key Companies
Chronic Otitis Media (COM) Key Products
Chronic Otitis Media (COM)- Unmet Needs
Chronic Otitis Media (COM)- Market Drivers and Barriers
Chronic Otitis Media (COM)- Future Perspectives and Conclusion
Chronic Otitis Media (COM) Analyst Views
Chronic Otitis Media (COM) Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Chronic Otitis Media (COM)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Chronic Otitis Media (COM)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Chronic Otitis Media (COM)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Chronic Otitis Media (COM)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
